GT201400063A - Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas - Google Patents

Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas

Info

Publication number
GT201400063A
GT201400063A GT201400063A GT201400063A GT201400063A GT 201400063 A GT201400063 A GT 201400063A GT 201400063 A GT201400063 A GT 201400063A GT 201400063 A GT201400063 A GT 201400063A GT 201400063 A GT201400063 A GT 201400063A
Authority
GT
Guatemala
Prior art keywords
quinasa
bub1
inhibitors
benzilindazols
replaced
Prior art date
Application number
GT201400063A
Other languages
English (en)
Inventor
Hitchcock Marion
Pütter Vera
Siemeister Gerhard
Wengner Antje Margret
Briem Hans
Eis Knut
Schulze Volker
Fernandez-Montalvan Amaury Ernesto
Prechtl Stefan
Holton Simon
Fanghänel Jörg
Lienau Philip
Preusse Cornelia
Gnoth Mark Jean
Mengel Anne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201400063A publication Critical patent/GT201400063A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01HNEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H6/00Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy
    • A01H6/36Ericaceae, e.g. azalea, cranberry or blueberry
    • A01H6/368Vaccinium, e.g. cranberry, blueberry
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Environmental Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LOS COMPUESTOS DE FÓRMULA (I) QUE SON INHIBIDORES DE QUINASA BUB1, PROCEDIMIENTOS PARA SU PRODUCCIÓN Y SU USO COMO PRODUCTOS FARMACÉUTICOS.
GT201400063A 2011-10-06 2014-04-04 Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas GT201400063A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11184061 2011-10-06

Publications (1)

Publication Number Publication Date
GT201400063A true GT201400063A (es) 2015-12-07

Family

ID=46968229

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400063A GT201400063A (es) 2011-10-06 2014-04-04 Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas

Country Status (38)

Country Link
US (3) US20140249133A1 (es)
EP (1) EP2763982B1 (es)
JP (1) JP6140170B2 (es)
KR (1) KR102007056B1 (es)
CN (1) CN103974948B (es)
AP (1) AP3847A (es)
AR (1) AR088449A1 (es)
AU (1) AU2012320582B2 (es)
BR (1) BR112014008045A2 (es)
CA (1) CA2851037A1 (es)
CO (1) CO6930363A2 (es)
CR (1) CR20140161A (es)
CU (1) CU20140043A7 (es)
CY (1) CY1120318T1 (es)
DK (1) DK2763982T3 (es)
DO (1) DOP2014000062A (es)
EA (1) EA201400412A1 (es)
EC (1) ECSP14013284A (es)
ES (1) ES2665036T3 (es)
GT (1) GT201400063A (es)
HK (1) HK1200449A1 (es)
HR (1) HRP20180546T1 (es)
HU (1) HUE037154T2 (es)
IL (1) IL231591A (es)
LT (1) LT2763982T (es)
MX (1) MX361279B (es)
NO (1) NO2763982T3 (es)
PE (1) PE20141203A1 (es)
PL (1) PL2763982T3 (es)
PT (1) PT2763982T (es)
RS (1) RS57099B1 (es)
SG (1) SG11201400616YA (es)
SI (1) SI2763982T1 (es)
TN (1) TN2014000138A1 (es)
TW (1) TWI588141B (es)
UA (1) UA111754C2 (es)
UY (1) UY34374A (es)
WO (1) WO2013050438A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
US9643953B2 (en) 2011-12-21 2017-05-09 Bayer Intellectual Property Gmbh Substituted benzylpyrazoles
CA2872933A1 (en) * 2012-05-11 2013-11-14 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment cancer
JP2016514717A (ja) * 2013-03-21 2016-05-23 バイエル ファーマ アクチエンゲゼルシャフト ジアミノヘテロアリール置換インダゾール
EP2976335A1 (en) * 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
US20160046610A1 (en) * 2013-03-21 2016-02-18 Bayer Pharma Aktiengesellschaft 3-heteroaryl substituted indazoles
CA2916097A1 (en) * 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
US9765058B2 (en) 2013-06-21 2017-09-19 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
EP3010911A1 (en) * 2013-06-21 2016-04-27 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
WO2014202586A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Diaminoheteroaryl substituted pyrazoles
CA2916194A1 (en) * 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
CA2928998A1 (en) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
TW201613886A (en) * 2014-06-17 2016-04-16 Bayer Pharma AG 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
US20170275269A1 (en) * 2014-09-19 2017-09-28 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
US20170305882A1 (en) * 2014-09-19 2017-10-26 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
EP3194378A1 (en) * 2014-09-19 2017-07-26 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles
AU2015316796A1 (en) 2014-09-19 2017-03-30 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as Bub1 inhibitors
GB201419264D0 (en) * 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
TN2017000329A1 (en) 2015-01-28 2019-01-16 Bayer Pharma AG 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
EP3636643A1 (en) * 2015-06-09 2020-04-15 AbbVie Inc. Nuclear receptor modulators (ror) for the treatment of inflammatory and autoimmune diseases
JP2018522847A (ja) * 2015-06-17 2018-08-16 バイエル ファーマ アクチエンゲゼルシャフト 3−アミノ−1,5,6,7−テトラヒドロ−4h−インドール−4−オン類
CN108602820A (zh) * 2015-12-16 2018-09-28 拜耳制药股份公司 杂-1,5,6,7-四氢-4h-吲哚-4-酮类化合物
WO2017148995A1 (en) 2016-03-04 2017-09-08 Bayer Pharma Aktiengesellschaft 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity
WO2017157992A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
WO2017157991A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
KR102048050B1 (ko) * 2019-08-29 2020-01-22 대한민국 Adb-푸비나카의 대사체 합성 방법
CN110684016A (zh) * 2019-09-27 2020-01-14 上海应用技术大学 一种含氟的azd9291衍生物及其制备方法和应用
JP2023543528A (ja) 2020-09-23 2023-10-16 スコーピオン セラピューティクス インコーポレイテッド がんの処置に有用なピロロ[3,2-c]ピリジン-4-オン誘導体
WO2022072634A1 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Bicyclic compounds for use in the treatment cancer
WO2022072645A2 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022094271A1 (en) 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
WO2022197913A1 (en) 2021-03-18 2022-09-22 Scorpion Therapeutics, Inc. Bicyclic derivatives which can be used to treat cancer
WO2023173083A1 (en) 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
WO2023178035A1 (en) 2022-03-14 2023-09-21 Slap Pharmaceuticals Llc Multicyclic compounds

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5470862A (en) 1995-02-03 1995-11-28 Ohmeda Pharmaceutical Products Division Inc. Substituted pyrazolyl compounds and methods employing such compounds
JP4351298B2 (ja) 1996-10-14 2009-10-28 バイエル・アクチエンゲゼルシヤフト 新規へテロシクリルメチル置換ピラゾール誘導体
DE19834047A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19846514A1 (de) * 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
ES2295441T3 (es) 2001-12-18 2008-04-16 MERCK & CO., INC. Moduladores de pirazol heteroaril sustituido de receptor 5 metabotropico de glutamato.
US7166293B2 (en) 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
BR0314196A (pt) 2002-09-10 2005-07-26 Scios Inc Inibidores de tgf-beta
DE10244810A1 (de) * 2002-09-26 2004-04-08 Bayer Ag Neue Morpholin-überbrückte Indazolderivate
WO2007038613A2 (en) 2005-09-26 2007-04-05 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
EP1709007A1 (en) 2004-01-22 2006-10-11 Altana Pharma AG N-4-(6-(heteo)aryl-pyrimidin-4-ylaminophenyl)-benzenesulfonamides as kinase inhibitors
WO2007065010A2 (en) * 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
BRPI0812361A2 (pt) 2007-05-18 2015-02-03 Bayer Schering Pharma Ag Derivados de pirazol heteroaril-substituídos úteis parao tratamento de distúrbios e doenças hiperproliferativos associados à angiogênese
JP2010111624A (ja) * 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
US8354399B2 (en) 2008-12-18 2013-01-15 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
WO2011049988A2 (en) 2009-10-20 2011-04-28 Eiger Biopharmaceuticals, Inc. Indazoles to treat flaviviridae virus infection
BR112012012617B8 (pt) 2009-11-27 2021-05-25 Adverio Pharma Gmbh processo para a produção de metil-{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
NZ603156A (en) 2010-03-30 2014-10-31 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
KR101813931B1 (ko) 2010-06-30 2018-01-02 아이언우드 파마슈티컬스, 인코포레이티드 Sgc 자극제
UA111754C2 (uk) * 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
US9643953B2 (en) 2011-12-21 2017-05-09 Bayer Intellectual Property Gmbh Substituted benzylpyrazoles
CA2861804C (en) 2011-12-27 2021-10-26 Ironwood Pharmaceuticals, Inc. 2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators
CA2872933A1 (en) 2012-05-11 2013-11-14 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment cancer
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
WO2014047325A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2014047662A2 (en) 2012-09-24 2014-03-27 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
JP2016514717A (ja) 2013-03-21 2016-05-23 バイエル ファーマ アクチエンゲゼルシャフト ジアミノヘテロアリール置換インダゾール
US20160046610A1 (en) 2013-03-21 2016-02-18 Bayer Pharma Aktiengesellschaft 3-heteroaryl substituted indazoles
EP2976335A1 (en) 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
CA2916097A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
CA2916194A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
EP3010911A1 (en) 2013-06-21 2016-04-27 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
US9765058B2 (en) 2013-06-21 2017-09-19 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
WO2014202586A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Diaminoheteroaryl substituted pyrazoles
CA2928998A1 (en) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
EP3194378A1 (en) 2014-09-19 2017-07-26 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles
US20170305882A1 (en) 2014-09-19 2017-10-26 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
US20170275269A1 (en) 2014-09-19 2017-09-28 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
AU2015316796A1 (en) 2014-09-19 2017-03-30 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as Bub1 inhibitors
WO2017148995A1 (en) 2016-03-04 2017-09-08 Bayer Pharma Aktiengesellschaft 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity
WO2017157991A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
WO2017157992A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors

Also Published As

Publication number Publication date
EP2763982B1 (en) 2018-01-10
US20140249133A1 (en) 2014-09-04
CY1120318T1 (el) 2019-07-10
ECSP14013284A (es) 2014-05-31
JP2014531465A (ja) 2014-11-27
CR20140161A (es) 2014-06-03
UY34374A (es) 2013-05-31
DK2763982T3 (en) 2018-04-23
WO2013050438A1 (en) 2013-04-11
TWI588141B (zh) 2017-06-21
AP2014007533A0 (en) 2014-03-31
HK1200449A1 (en) 2015-08-07
MX2014004122A (es) 2014-06-04
HRP20180546T1 (hr) 2018-05-04
KR102007056B1 (ko) 2019-08-02
CN103974948A (zh) 2014-08-06
LT2763982T (lt) 2018-04-25
NO2763982T3 (es) 2018-06-09
AP3847A (en) 2016-09-30
JP6140170B2 (ja) 2017-05-31
TN2014000138A1 (en) 2015-09-30
NZ623098A (en) 2016-09-30
PT2763982T (pt) 2018-04-16
AR088449A1 (es) 2014-06-11
BR112014008045A2 (pt) 2017-04-11
US10604532B2 (en) 2020-03-31
AU2012320582A1 (en) 2014-04-17
ES2665036T3 (es) 2018-04-24
SG11201400616YA (en) 2014-09-26
CO6930363A2 (es) 2014-04-28
SI2763982T1 (en) 2018-06-29
PL2763982T3 (pl) 2018-07-31
IL231591A (en) 2016-09-29
EP2763982A1 (en) 2014-08-13
PE20141203A1 (es) 2014-10-01
RS57099B1 (sr) 2018-06-29
DOP2014000062A (es) 2014-07-15
US20190284206A1 (en) 2019-09-19
UA111754C2 (uk) 2016-06-10
CU20140043A7 (es) 2014-08-28
EA201400412A1 (ru) 2014-08-29
MX361279B (es) 2018-12-03
AU2012320582B2 (en) 2017-06-15
US10266548B2 (en) 2019-04-23
KR20140075775A (ko) 2014-06-19
IL231591A0 (en) 2014-05-28
TW201321370A (zh) 2013-06-01
CA2851037A1 (en) 2013-04-11
CN103974948B (zh) 2017-07-28
HUE037154T2 (hu) 2018-08-28
US20170260198A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CR20150326A (es) Inhibidores de autotaxina
UY35467A (es) Compuestos orgánicos
ECSP15008851A (es) Compuestos heteroaromáticos como inhibidores de btk
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
DOP2015000157A (es) Lactamas fusionadas de arilo y heteroarilo
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
CO7210068A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
NI201500077A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
PE20151023A1 (es) Triazolopirazinas
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
CO6781507A2 (es) Novedosos derivados heterociclicos
ECSP14013215A (es) Compuestos novedosos
CO6670575A2 (es) Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
UY35827A (es) Derivados de triazolopirazina como inhibidores de la proteína brd4
CU24263B1 (es) Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
UY34356A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
NI201500050A (es) Benzamidas
CR20110210A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
UY34166A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib